Bowel cancer screening is detecting approximately 100 cancers every week among people in their 50s in England, according to annual figures released by NHS England — yet the data also shows that this age group is among the least likely to complete and return their screening kits.
Participation Rates Among Those in Their 50s
The figures, which cover the period from April 2024 to March 2025, indicate that just over half of 54-year-olds — 56.2%, according to NHS England's annual bowel screening statistics — took part in the programme during that year. That proportion is notably lower than uptake recorded in older age groups, raising concerns among public health officials about a gap in early detection at a stage when intervention may be most effective.
Bowel cancer is one of the most common cancers diagnosed in the United Kingdom. When detected at an early stage, outcomes are generally more favourable, which is the central rationale behind population-level screening programmes. The fact that the programme is already identifying around 100 cases weekly among people in their 50s suggests the test is functioning as intended for those who do participate — but the relatively modest participation rate implies a substantial number of potential cases may be going undetected.
How the Screening Process Works
The NHS bowel cancer screening programme sends home testing kits — known as faecal immunochemical tests, or FITs — to eligible individuals. The test involves collecting a small stool sample, which is then returned by post for laboratory analysis. A positive result triggers a referral for further investigation, typically a colonoscopy. The process is designed to be completed without a clinic visit, removing some of the logistical barriers associated with other forms of cancer screening.
Despite this convenience, return rates among younger eligible adults have consistently lagged. Researchers and public health analysts have previously noted that people in their 50s may perceive themselves as lower risk, or may be less engaged with health services generally, compared with those in their 60s and 70s.
Why the 50s Age Group Matters
The extension of bowel screening eligibility to people in their 50s — a relatively recent expansion of the programme — was intended precisely to capture cancers and pre-cancerous polyps at an earlier stage. The weekly detection figure of 100 cancers in this cohort underscores that the disease is not uncommon in this demographic, even if it is sometimes assumed to be predominantly a condition of older age.
Earlier detection is associated with a wider range of treatment options and, in many cases, less extensive intervention. Cancers identified at a localised stage, before spread to surrounding tissue or distant organs, are generally more amenable to surgical removal and carry a more favourable prognosis, as noted in broader oncological literature.
Barriers to Uptake
Low participation in cancer screening is a well-documented public health challenge. Studies published in journals including the British Journal of Cancer have identified a range of factors that influence whether individuals complete home-based tests, including health literacy, cultural attitudes toward cancer, practical concerns about the testing process, and a lack of awareness that an invitation has been received.
Deprivation has also been linked to lower screening uptake in multiple analyses. Areas with higher levels of socioeconomic disadvantage tend to show reduced participation rates, which can compound existing health inequalities if cancers in those populations are consequently diagnosed at a later stage.
The Scale of the Detection Gap
If 56.2% of 54-year-olds participated during 2024–25, that means roughly four in ten people in that specific age bracket did not return their kits. Extrapolated across the broader population of people in their 50s who are sent invitations each year, the number of non-participants is substantial. NHS England's public health messaging has focused on encouraging this group to act on their invitations, framing kit completion as a straightforward step with potentially significant consequences for early detection.
The annual figures serve as a reminder that screening programmes are only as effective as their participation rates allow. A test that reliably finds cancer — as the current data suggests this one does — offers limited population-level benefit if a meaningful share of those invited do not engage with it.